Nav: Home

Cryoablation comparable to surgery for treating early-stage kidney cancer

June 09, 2020

OAK BROOK, Ill. - A minimally invasive procedure that destroys cancer cells by freezing them is as effective as surgery for treating early-stage kidney cancer, offering similar 10-year survival rates with a lower rate of complications, according to a study published in the journal Radiology.

Kidney cancer is among the 10 most common cancers in men and women in the United States. About 70% of cases are found at stage 1, the earliest stage. Treatment typically involves surgical removal of the tumor from the kidney, also known as a partial nephrectomy. Radical nephrectomy, or removal of the entire kidney, is another surgical option.

Percutaneous cryoablation (PCA) has emerged as an alternative to surgery that kills the tumor by freezing it. In the procedure, an interventional radiologist inserts a hollow needle into the tumor under imaging guidance. Argon gas circulating through the needle freezes a small volume of tissue, including the tumor and a small amount of normal tissue around it. The tumor dies, and over time it turns into scar tissue that is absorbed by the body.

"We have been doing cryoablation with increasing frequency at Johns Hopkins," said study lead author Christos S. Georgiades, M.D., Ph.D., professor of radiology, oncology and surgery from the Department of Vascular and Interventional Radiology at Johns Hopkins University in Baltimore. "It's an outpatient procedure that takes about 30 to 40 minutes to perform. We observe the patient for three hours, and then they can go home."

For the study, Dr. Georgiades and colleagues looked at 134 patients who underwent cryoablation for early-stage kidney cancer and compared their outcomes over 10 years with those of patients who had either a radical or partial nephrectomy.

Disease-specific survival--that is, the proportion of patients who were still alive or had died from some other cause besides kidney cancer--was 94% at both five and 10 years after treatment, a figure comparable to that reported after radical or partial nephrectomy. Overall survival probability after percutaneous cryoablation at five and 10 years was longer than for radical or partial nephrectomy.?

"For certain patients, cryoablation is equivalent to surgery with fewer side effects," Dr. Georgiades said. "The risk of significant complications from this procedure is about 6%, compared to between 15 and 20% for surgery. In addition, recovery is much faster than with surgery."

The study also found that cryoablation was associated with a low 10-year risk of hemodialysis.

Dr. Georgiades emphasized that cryoablation is only appropriate for early-stage kidney cancer that is confined to the kidney and is up to about 4 centimeters in size. It would not be effective in larger tumors. He doesn't treat patients with cryoablation unless they see a urologist first to get briefed on the surgical option.

"If a patient is interested in hearing about cryoablation, I'll explain the risks, benefits and outcomes," Dr. Georgiades said. "At Johns Hopkins, we give patients all the options and, in the end, they make the final decision. I only offer cryoablation if I know it's going to be beneficial to the patient."

As of now, the standard of care for early-stage kidney cancer is partial nephrectomy. However, the study results from Johns Hopkins, along with results from other studies, are likely to be considered by medical societies as they update their guidelines.

"Studies like this may convince societies to make cryoablation the go-to option, at least for early-stage kidney cancer," Dr. Georgiades said.
"Percutaneous Cryoablation for Stage 1 Renal Cell Carcinoma: Outcomes from a 10-year, Prospective Study and Comparison with Matched Cohorts from the National Cancer Database." Collaborating with Dr. Georgiades were John Morkos, B.S., Kori A. Porosnicu Rodriguez, B.A., Alice Zhou, B.S., Andrew R. Kolarich, M.D., Constantine Frangakis, Ph.D., and Ronald Rodriguez, M.D., Ph.D.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, and owned and published by the Radiological Society of North America, Inc. (

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (

For patient-friendly information on cryoablation, visit

Radiological Society of North America

Related Kidney Cancer Articles:

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.
Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.
Cutting off kidney cancer at its roots
Scientists at the MDC have discovered stem cells responsible for the most common form of kidney cancer.
Finding familiar pathways in kidney cancer
The famous cancer gene p53, which was thought to be less relevant in kidney cancer, may play a larger role than previously appreciated, suggesting new potential for treatment.
Root of childhood kidney cancer discovered
A fundamental change in our understanding of the childhood kidney cancer Wilms' tumor is on the horizon, after the discovery of its earliest genetic root by scientists at the Wellcome Sanger Institute and their collaborators.
Kidney-resident macrophages -- a role for healing during acute kidney injury?
Researchers have found that, during acute kidney injury in a mouse model, the kidney-resident macrophages are reprogrammed to a developmental state, resembling these same cells when they are found in newborn mice.
Antibodies to a retina protein to be used as a kidney cancer marker
Sechenov University together with their German colleagues suggest a new highly sensitive, quick, and pain-free method for diagnosing kidney cancer.
Revealed: 35 kidney genes linked to chronic kidney disease risk
An international study lead by University of Manchester scientists has discovered the identity of genes that predispose people to chronic kidney disease.
High-dose, high-precision radiation therapy safe, effective for solitary kidney cancer patients with only one kidney
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment.
Kidney cancer's developmental source revealed
In the first experiment of its kind, scientists have revealed the precise identity of cancer cells of the most common childhood and adult kidney cancers.
More Kidney Cancer News and Kidney Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.